由Informa Pharmaceutical Science出版(原Ashley Publications)。ISSN: 1472 - 8222?！吨委煱袠说膶＜乙庖姟肥且槐局铝τ谏钊雸蟮篮驮u論藥物靶標發(fā)現(xiàn)和驗證領(lǐng)域最新進展的權(quán)威雜志?！吨委煱袠说膶＜乙庖姟肥且环萃性u議的期刊，提供對最近發(fā)現(xiàn)新的分子藥物靶標的研究的評估和專家評議。該雜志提供了生物途徑和相互作用的基礎(chǔ)研究與未來藥物開發(fā)之間的重要聯(lián)系。它與其他出版物的不同之處在于其高質(zhì)量的作者和專業(yè)起草的文章，這些文章的結(jié)構(gòu)吸收了作者自己在這個問題上的專業(yè)知識。觀眾包括制藥行業(yè)的科學家、經(jīng)理和決策者，以及與研發(fā)密切相關(guān)的其他人。用戶包括美國、歐洲和日本的大多數(shù)主要制藥公司，以及許多生物技術(shù)公司。

Published by Informa Pharmaceutical Science (formerly Ashley Publications). ISSN: 1472-8222.Expert Opinion on Therapeutic Targets is the premier journal dedicated to in-depth reports and reviews of the latest developments in the field of drug target discovery and validation. Expert Opinion on Therapeutic Targets is a peer-reviewed journal providing evaluated and expert reviews of recent research identifying novel molecular drug targets. The journal provides an essential link between basic research on biological pathways and interactions, and the development of the drugs of tomorrow. It is distinguished from other publications by its high-quality authorship and expertly drafted articles which are structured to incorporate the author's own expertise on the subject. The audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, as well as many biotechnology companies.